Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis

AIM: We comprehensively analyzed how hepatitis C virus (HCV) eradication by interferon (IFN)-free direct-acting-antiviral-agents (DAAs) affects liver steatosis and atherogenic risk. METHODS: Patients treated with IFN-free-DAAs who underwent transient elastography before and at 24-weeks post-treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawagishi, Naoki, Suda, Goki, Nakamura, Akinobu, Kimura, Megumi, Maehara, Osamu, Suzuki, Kazuharu, Nakamura, Akihisa, Ohara, Masatsugu, Izumi, Takaaki, Umemura, Machiko, Nakai, Masato, Sho, Takuya, Natsuizaka, Mitsuteru, Morikawa, Kenichi, Ogawa, Koji, Kudo, Yusuke, Nishida, Mutsumi, Miyoshi, Hideaki, Sakamoto, Naoya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6303061/
https://www.ncbi.nlm.nih.gov/pubmed/30576386
http://dx.doi.org/10.1371/journal.pone.0209615

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6303061/
https://www.ncbi.nlm.nih.gov/pubmed/30576386
http://dx.doi.org/10.1371/journal.pone.0209615

Ejemplares similares